Filing Analysis
IGC Pharma, Inc. entered into an amendment on June 5, 2026, to extend its existing Master Loan and Security Agreement with O-Bank Co., Ltd. The extension maintains a maximum aggregate credit limit of $12,000,000.
📋 Key Facts
- Agreement date: June 5, 2026
- Lender: O-Bank Co., Ltd. (Taiwan)
- Maximum aggregate facility limit: $12,000,000
- Facility fee increased from $48,000 to $60,000
- Material terms remain substantially unchanged from the June 24, 2025 facility letter
IGC Pharma, Inc. entered into two securities purchase agreements for promissory notes totaling $584,960 in principal, yielding $514,000 in net proceeds after original issue discounts. The notes carry a 12% interest rate and include a default-triggered conversion feature allowing holders to convert debt into equity at a 25% discount to the lowest recent trading price.
🚩 Red Flags
- High cost of capital: Total original issue discount of $70,960 on $514,000 of cash (nearly 14% upfront cost).
- Toxic conversion feature: The 25% discount to the 'lowest trading price' upon default is a characteristic of dilutive 'death spiral' financing.
- Small financing size: Raising only ~$514k for a pharma company suggests immediate and potentially desperate liquidity needs for working capital.
📋 Key Facts
- Issued a $346,910 principal note to FirstFire Global Opportunities Fund, LLC for $307,000 in cash (approx. 11.5% OID).
- Issued a $238,050 principal note to Vanquish Funding Group Inc. for $207,000 in cash (approx. 13% OID).
- Both notes carry a 12% interest rate and mature in late March/early April 2027.
- Upon an Event of Default, notes are convertible into common stock at 75% of the lowest trading price during the 10 days preceding conversion.
- Proceeds are intended for general working capital purposes.
IGC Pharma, Inc. has entered into a strategic national media partnership with FMW Media Works LLC (New to The Street) to bolster its investor relations and corporate communications.
🚩 Red Flags
- The use of 'New to The Street', a sponsored media platform, is a common tactic for micro-cap companies to increase visibility, which can sometimes be associated with high-cost IR campaigns.
📋 Key Facts
- The partnership was announced on March 30, 2026.
- The counterparty is FMW Media Works LLC, operating the 'New to The Street' financial media platform.
- The initiative is focused on investor relations and corporate communications.
- The disclosure was made under Item 8.01 (Other Events) and is considered furnished rather than filed.
IGC Pharma entered into two separate debt financing arrangements totaling approximately $526,000 in net proceeds for working capital. The primary $353,050 note includes a significant original issue discount and a variable-rate conversion feature triggered by default.
🚩 Red Flags
- High cost of capital: The VFG note carries a ~15% original issue discount relative to cash received.
- Toxic conversion terms: The 25% discount to the lowest trading price (death spiral provision) upon default is highly dilutive.
- Small financing amounts: Raising less than $600,000 across two lenders suggests constrained liquidity and limited access to traditional credit.
- Multiple debt instruments: Two separate financing events reported in a single filing.
📋 Key Facts
- Entered into a Securities Purchase Agreement with Vanquish Funding Group (VFG) for a $353,050 Promissory Note.
- The VFG Note included an original issue discount (OID) of $46,050, resulting in net proceeds of $307,000.
- The VFG Note matures on February 28, 2027, and features a default conversion price of 75% of the lowest trading price during the 10 days preceding conversion.
- Obtained a second loan from One Deck Capital, Inc. for approximately $219,000.
- Proceeds from both loans are designated for general working capital purposes.